Whitnell & Co’s TherapeuticsMD TXMD Stock Holding History

Whitnell & Co’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1	Closed	–	–	400
2015 Q2	$0	Hold	1	–	–	﹤0.01%	265
2015 Q1	$0	Buy	+1	New	+$244	﹤0.01%	273

Other funds holding TXMD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Whitnell & Co's TXMD Position: Q3 2015 in Review

Whitnell & Co sold out of TherapeuticsMD (TXMD) in Q3 2015, closing a stake of 1 share.

Whitnell & Co first reported a position in TXMD in Q1 2015 and held it in 2 quarters. The position peaked at $0 in Q2 2015. 114 funds tracked by Wall St. Rank hold TXMD as of Q3 2015.

Whitnell & Co reported no remaining TherapeuticsMD position as of Q3 2015 after selling out during the quarter.
Whitnell & Co sold 1 TherapeuticsMD share in Q3 2015.
Whitnell & Co first reported a position in TherapeuticsMD in Q1 2015 and held it in 2 quarters.
Whitnell & Co's TherapeuticsMD position peaked at $0 in Q2 2015.
114 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2015.

Based on Whitnell & Co's 13F filing for Q3 2015, filed 10 Nov 2015.